Taiho Oncology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Taiho Oncology sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials 7 currently recruiting 23 completed early-phase tilt top decile by trial count

Taiho Oncology: 52 sponsored US clinical trials, 7 recruiting.

Taiho Oncology sponsors 52 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 23 completed. 8 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 4 trials.

Top-decile sponsor footprint

Taiho Oncology ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

23 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

52 total, page 1 of 2

RECRUITING Phase 1

A Study of ARC-02 in B-cell NHL

NCT07691606
RECRUITING Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
RECRUITING Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689
RECRUITING Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176
RECRUITING Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

NCT04953910
RECRUITING Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897
RECRUITING Phase 2

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317
ACTIVE NOT RECRUITING Phase 3

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
ACTIVE NOT RECRUITING Phase 2

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

NCT05945823
ACTIVE NOT RECRUITING Phase 1

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05403450
ACTIVE NOT RECRUITING Phase 1

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081
ACTIVE NOT RECRUITING Phase 1

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

NCT02503423
TERMINATED Phase 1

A Study of TAS3351 in NSCLC Patients With EGFRmt

NCT05765734
TERMINATED Phase 1

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

NCT04965818
TERMINATED Phase 1

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

NCT04982926
TERMINATED Phase 1

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

NCT04770246
TERMINATED Phase 2

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

NCT04601857
TERMINATED Phase 3

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04093362
COMPLETED Phase 3

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

NCT04737187
TERMINATED Phase 1

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

NCT04586270
TERMINATED Phase 2

Futibatinib in Patients With Specific FGFR Aberrations

NCT04189445
TERMINATED Phase 1

A Study of TAS1440 With ATRA in Subjects With r/r AML

NCT04282668
TERMINATED Phase 2

A Study of TAS-120 in Patients With Metastatic Breast Cancer

NCT04024436
TERMINATED Phase 1

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

NCT03975387
COMPLETED Phase 1

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

NCT03502668
COMPLETED Phase 1

Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075
TERMINATED Phase 1

A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

NCT03410927
COMPLETED Phase 1

A Study of TAS-116 in Patients With Solid Tumors

NCT02965885
TERMINATED

The CHOICE Registry

NCT03148093
TERMINATED Phase 1

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

NCT02978235
COMPLETED Phase 2

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

NCT02860546
COMPLETED Phase 2

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125
COMPLETED Phase 1

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

NCT02566772
COMPLETED Phase 3

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

NCT02500043
COMPLETED Phase 1

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

NCT02301117
COMPLETED Phase 1

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

NCT02301104
TERMINATED Phase 1

An Investigation of TAS-119 Monotherapy

NCT02448589
TERMINATED Phase 1

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT02134067
COMPLETED Phase 1

A Study of TAS-120 in Patients With Advanced Solid Tumors

NCT02052778
COMPLETED Phase 1

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

NCT02031055
COMPLETED Phase 1

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

NCT01916447
COMPLETED Phase 1

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

NCT01874522
COMPLETED Phase 1

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

NCT01867879
COMPLETED Phase 1

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

NCT01867866
COMPLETED Phase 1

A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

NCT02025803
COMPLETED Phase 3

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

NCT01607957
TERMINATED Phase 3

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

NCT01285557
COMPLETED Phase 1

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

NCT00400023
COMPLETED Phase 1

Evaluating Patients With Impaired Hepatic Function

NCT00398424
COMPLETED Phase 1

Evaluating Patients With Varying Degrees of Renal Function

NCT00398307
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 34
Phase 2 9
Phase 3 8

Therapeutic Areas

Acute Myeloid Leukemia 4
Myelodysplastic Syndromes 4
Advanced Solid Tumors 2
Relapsed/Refractory Peripheral T-cell Lymphoma 1
Siewert Type 1 GEJ Cancer 1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer 1
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation 1
Esophageal Squamous Cell Cancer 1
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations 1
Uncommon EGFR Mutations 1

What is open in the Taiho Oncology pipeline

7 recruiting of 52 indexed (13% open); 23 completed (44%).

Phase mix: 8 late (III/IV) vs 43 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Taiho Oncology: open-pipeline peers nationwide

Peers matched on 52 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Taiho OncologyAlbany Medical CollegeBurzynski Research InstituteDr. Reddy's Laboratories LimitedPTC TherapeuticsUniversity of MichiganWayne State UniversityCase Comprehensive Cancer CenterBeth Israel Deaconess Medical Center
Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Taiho Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Taiho Oncology page

52 registered trials is a research-attention snapshot, not an endorsement of Taiho Oncology or any single study.

  • 7 of Taiho Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myeloid Leukemia is the condition Taiho Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Taiho Oncology pipeline card: 52 registered trials from official public datasets.Report a data error.